Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-2378-2012

The product affected by this notice is sold under the trade name TomoTherapy SharePlan 1.1. To determine if the version you are using is affected, bring up the About box in the SharePlan application and check if the build number reported there is 1.3.1.10. Intended use: t-RayAutoplan is a software that, based on the planned dose distribution from a TomoPlan treatment planning system, generates a family of individually optimized IMRT plans and presents their characteristics to the user in a GUI. Among the generated plans, the user selects and clinically approves a treatment plan and exports it electronically to DICOM, for subsequent treatment of the patient. The intended users of t-RayAutoplan shall be clinically qualified staff, such as medical physicists, medical doctors or dosimetrists

Publicado el 26 de septiembre de 2012 · Inicio del retiro: 30 de mayo de 2011

Resumen

FDA registra el retiro Z-2378-2012 de dispositivos médicos de Clase II, publicado el 26 de septiembre de 2012 e iniciado el 30 de mayo de 2011. Empresa responsable: RAYSEARCH LABORATORIES AB; Estado: Finalizado; Cantidad reportada: 15 units; Lote: SharePlan 1.1, aka t-RayAutoplan version 1.2.1 (build number 1.3.1.10). La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

This field notice concerns two behaviors of the SharePlan (Multiple Fraction Groups and Depth Offset) that may be unexpected and are not clearly described in the user manual. None of these behaviors have caused patient mistreatment or other incidents. However, the described user actions must be adhered to for best agreement between treatment plan evaluation and the clinical outcome of the delivere

Qué hacer

Voluntary: Firm initiated · Letter

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
RAYSEARCH LABORATORIES AB
Distribuidor
Worldwide Distribution - USA including CA, KY, MI, NY, OK, and OR. Internationally to Canada, Belgium, United Kingdom, Australia, France, Germany, and Poland.
Lote
SharePlan 1.1, aka t-RayAutoplan version 1.2.1 (build number 1.3.1.10).
Clasificación de riesgo
Class II
Área (FDA)
device
País
Sweden

Retiros relacionados

Preguntas sobre este retiro

¿The product affected by this notice is sold under the trade name TomoTherapy SharePlan 1.1. To determine if the version you are using is affected, bring up the About box in the SharePlan application and check if the build number reported there is 1.3.1.10. Intended use: t-RayAutoplan is a software that, based on the planned dose distribution from a TomoPlan treatment planning system, generates a family of individually optimized IMRT plans and presents their characteristics to the user in a GUI. Among the generated plans, the user selects and clinically approves a treatment plan and exports it electronically to DICOM, for subsequent treatment of the patient. The intended users of t-RayAutoplan shall be clinically qualified staff, such as medical physicists, medical doctors or dosimetrists fue retirado del mercado?

Sí. FDA publicó el retiro Z-2378-2012 el 26 de septiembre de 2012. Peligro reportado: This field notice concerns two behaviors of the SharePlan (Multiple Fraction Groups and Depth Offset) that may be unexpected and are not clearly described in the user manual. None of these behaviors have caused patient mistreatment or other incidents. However, the described user actions must be adhered to for best agreement between treatment plan evaluation and the clinical outcome of the delivere

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Letter